-
Biogen Reveals $900M Settlement In Whistleblower's MS Drug Kickbacks Lawsuit Days Before Trial
Thursday, July 21, 2022 - 2:15am | 361Read More...Biogen, Inc. (NASDAQ: BIIB) disclosed in its second-quarter earnings report that it recorded $900 million related to a settlement agreement to resolve previously disclosed "qui tam" litigation related to its conduct before 2015. Qui tam is a type of whistleblower...
-
Breaking Down The Multiple Sclerosis 2017 Formularies: 'Stability Fares Well For The Market'
Thursday, February 23, 2017 - 3:06pm | 615Read More...Offering its insight into the formulary coverage of multiple sclerosis drugs for 2017, Bernstein said in a note released on Thursday it sees stabilization of formulary coverage after a year of tightening in 2016. Treatment Options MS is a neurodegenerative disease affecting young adults,...
-
Biogen Optionality Looking Attractive; Bernstein Initiates At Outperform
Wednesday, June 29, 2016 - 1:56pm | 242Read More...Biogen Inc (NASDAQ: BIIB) has an aging MS franchise, but a solid biosimilar pipeline is sure to offset the loss of Tecfidera, Avonex and Tysabri. Bernstein's Aaron Gal initiated Biogen at outperform and set a price target of $282. The multiple sclerosis franchise has a five-year runway as...
-
Nomura's Takeways From Biogen Idec's Analyst Meeting
Friday, January 16, 2015 - 12:06pm | 205Read More...Ian Somaiya on Friday commented in a note that Biogen Idec Inc's (NASDAQ: BIIB) management team during a recent analyst meeting pointed to potential reasons for the recent slowdown in Ecfidera uptake. According to Somaiya, Biogen noted: "1) The burst of active switching caused by...
